Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL27590383 | 0.84 | FFAR1 (0.48) | FFAR1FFAR4HDAC1HDAC6PTGDR2 | |
| SCHEMBL532567 | 0.82 | EGLN2 (0.48) | ALDH1A1CYP2A6FFAR1FFAR4EGLN2 | |
| SCHEMBL31442843 | 0.81 | GRM5 (0.44) | FFAR1FFAR4HDAC1HDAC6ACHE | |
| SCHEMBL7859984 | 0.79 | GRM5 (0.43) | FFAR1FFAR4HDAC1HDAC6ACHE | |
| SCHEMBL29416796 | 0.78 | EGLN2 (0.44) | ALDH1A1CYP2A6EGLN2KIF11 | |
| SCHEMBL229147 | 0.78 | EGLN2 (0.44) | ALDH1A1CYP2A6EGLN2KIF11 | |
| SCHEMBL29814587 | 0.78 | CYP2A6 (0.52) | ALDH1A1CYP2A6FFAR1EGLN2AR | |
| SCHEMBL1436903 | 0.78 | CYP2A6 (0.52) | ALDH1A1CYP2A6FFAR1EGLN2AR | |
| SCHEMBL21020660 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP2A6FFAR1FFAR4EGLN2 | |
| SCHEMBL7857630 | 0.77 | HDAC8 (0.38) | HDAC8HDAC1HDAC6ACHENISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816874-B | Process method for synthesizing 4-cyano-2-fluorobenzyl alcohol | 大连双硼医药化工有限公司 | 2024-01-26 | — | — | CN | claimed |
| WO-2023099777-A1 | METHOD OF UNDERWATER BONDING | Henkel IP & Holding GmbH (DE) | 2023-06-08 | — | — | WO | claimed |
| CN-109400500-B | Preparation method of 3-fluoro-4-methylbenzonitrile | 浙江天宇药业股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-113816874-A | Process method for synthesizing 4-cyano-2-fluorobenzyl alcohol | 大连双硼医药化工有限公司 | 2021-12-21 | — | — | CN | claimed |
| EP-2471769-A1 | Process for preparing a benzonitrile derivative | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | claimed |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | claimed |
| EP-2295417-A1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | Bristol-Myers Squibb Company (US) | 2011-03-16 | — | — | EP | claimed |
| EP-3887359-B1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | UNIV COPENHAGEN (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20240391908-A1 | METABOLITES OF GLP1R AGONISTS | PFIZER INC. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET [DK]/[DK] (DK) | 2024-08-29 | — | — | US | disclosed |
| US-12065434-B2 | Metabolites of GLP1R agonists | PFIZER INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0154840-B1 | LIQUID CRYSTAL COMPOUNDS | MERCK PATENT GmbH (DE) | 1989-01-25 | — | — | EP | disclosed |
| US-4784471-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-11-15 | — | — | US | disclosed |
| US-4704227-A | DERIVATIVES OF 1,3-DIOXANE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-11-03 | — | — | US | disclosed |
| EP-0211876-A1 | FLUOROBENZENE DERIVATIVES | MERCK PATENT GmbH (DE) | 1987-03-04 | — | — | EP | disclosed |
| WO-1986004895-A1 | FLUOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-08-28 | — | — | WO | disclosed |
| EP-0154840-A2 | Liquid crystal compounds | MERCK PATENT GmbH (DE) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3639/4885CYP2A6 1848/4885FFAR1 1761/4885 |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | ALDH1A1 2958/4885CYP2A6 4092/4885FFAR1 2641/4885 |
| US-12065434-B2 | Metabolites of GLP1R agonists | GLP1R, GCGR, GIPR | ALDH1A1 1781/4885CYP2A6 436/4885FFAR1 21/4885 |
| US-20240391908-A1 | METABOLITES OF GLP1R AGONISTS | GLP1R, GCGR, GIPR | ALDH1A1 1781/4885CYP2A6 436/4885FFAR1 21/4885 |
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | HUNK, NUCB2, TK1 | ALDH1A1 2499/4885CYP2A6 4728/4885FFAR1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.